Biopharma company faces pressure to trim costs and maximize value for shareholders
May 22, 2021 at 07:54 AM EDT
Alkermes, a biopharmaceutical company, benefits from profitable drugs and royalties, but a “bloated cost structure” keeps it from being profitable.
